Terms: = Lung cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras AND Clinical Outcome
16 results:
1. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in k-ras-driven cancer.
Glorieux C; Xia X; You X; Wang Z; Han Y; Yang J; Noppe G; Meester C; Ling J; Robert A; Zhang H; Li SP; Wang H; Chiao PJ; Zhang L; Li X; Huang P
J Adv Res; 2022 Sep; 40():109-124. PubMed ID: 36100320
[TBL] [Abstract] [Full Text] [Related]
2. A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer.
Hernández-Prieto S; Romera A; Ferrer M; Subiza JL; López-Asenjo JA; Jarabo JR; Gómez AM; Molina EM; Puente J; González-Larriba JL; Hernando F; Pérez-Villamil B; Díaz-Rubio E; Sanz-Ortega J
Clin Transl Oncol; 2015 Apr; 17(4):330-8. PubMed ID: 25301404
[TBL] [Abstract] [Full Text] [Related]
3. [Correlation analysis between abundance of k-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
[TBL] [Abstract] [Full Text] [Related]
4. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ
Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457
[TBL] [Abstract] [Full Text] [Related]
5. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.
John T; Kohler D; Pintilie M; Yanagawa N; Pham NA; Li M; Panchal D; Hui F; Meng F; Shepherd FA; Tsao MS
Clin Cancer Res; 2011 Jan; 17(1):134-41. PubMed ID: 21081655
[TBL] [Abstract] [Full Text] [Related]
6. Pulmonary adenocarcinoma with microcystic histology and intratumoral heterogeneity of EGFR gene polymorphism.
Yeh YC; Chou TY
Histopathology; 2010 Jul; 57(1):112-20. PubMed ID: 20653783
[TBL] [Abstract] [Full Text] [Related]
7. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E; Zucali PA; Peters GJ; Cortesi F; D'Incecco A; Smit EF; Falcone A; Burgers JA; Santoro A; Danesi R; Giaccone G; Tibaldi C
Mol Cancer Ther; 2010 Mar; 9(3):581-93. PubMed ID: 20159991
[TBL] [Abstract] [Full Text] [Related]
8. clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and k-ras mutation status.
Kalikaki A; Koutsopoulos A; Hatzidaki D; Trypaki M; Kontopodis E; Stathopoulos E; Mavroudis D; Georgoulias V; Voutsina A
Lung Cancer; 2010 Jul; 69(1):110-5. PubMed ID: 19854533
[TBL] [Abstract] [Full Text] [Related]
9. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.
Shibata T; Hanada S; Kokubu A; Matsuno Y; Asamura H; Ohta T; Sakamoto M; Hirohashi S
Cancer Sci; 2007 Jul; 98(7):985-91. PubMed ID: 17459062
[TBL] [Abstract] [Full Text] [Related]
10. A modified mutagenic PCR-RFLP method for k-ras codon 12 and 13 mutations detection in NSCLC patients.
Hatzaki A; Razi E; Anagnostopoulou K; Iliadis K; Kodaxis A; Papaioannou D; Labropoulos S; Vasilaki M; Kosmidis P; Saetta A; Mihalatos M; Nasioulas G
Mol Cell Probes; 2001 Oct; 15(5):243-7. PubMed ID: 11735295
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of k-ras gene mutations in lung carcinomas: correlation with gender, histological subtypes, and clinical outcome.
Wang YC; Lee HS; Chen SK; Yang SC; Chen CY
J Cancer Res Clin Oncol; 1998; 124(9):517-22. PubMed ID: 9808427
[TBL] [Abstract] [Full Text] [Related]
12. Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors.
Rosell R; Pifarré A; Monzó M; Astudillo J; López-Cabrerizo MP; Calvo R; Moreno I; Sanchez-Céspedes M; Font A; Navas-Palacios JJ
Int J Cancer; 1997 Jun; 74(3):330-4. PubMed ID: 9221814
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic value of replication errors on chromosomes 2p and 3p in non-small-cell lung cancer.
Pifarré A; Rosell R; Monzó M; De Anta JM; Moreno I; Sánchez JJ; Ariza A; Mate JL; Martińez E; Sánchez M
Br J Cancer; 1997; 75(2):184-9. PubMed ID: 9010024
[TBL] [Abstract] [Full Text] [Related]
14. k-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.
Lee JC; Wang ST; Lai MD; Lin YJ; Yang HB
Anticancer Res; 1996; 16(6B):3839-44. PubMed ID: 9042267
[TBL] [Abstract] [Full Text] [Related]
15. Bronchioloalveolar lung carcinomas: k-ras mutations are constant events in the mucinous subtype.
Marchetti A; Buttitta F; Pellegrini S; Chella A; Bertacca G; Filardo A; Tognoni V; Ferreli F; Signorini E; Angeletti CA; Bevilacqua G
J Pathol; 1996 Jul; 179(3):254-9. PubMed ID: 8774479
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of p53, k-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract] [Full Text] [Related]
